Loading...
Loading...
ERNA| Name | Value |
|---|---|
| Revenues | 47.0K |
| Cost of Revenue | 602.0K |
| Gross Profit | -555.0K |
| Operating Expense | 5,232.0K |
| Operating I/L | -5,787.0K |
| Other Income/Expense | -856.0K |
| Interest Income | 0.0K |
| Pretax | -6,643.0K |
| Income Tax Expense | 4.0K |
| Net Income/Loss | -6,647.0K |
Brooklyn ImmunoTherapeutics, Inc. is a clinical stage biopharmaceutical company specializing in developing innovative therapies for cancer treatment. Its primary focus is on the advancement of IRX-2, currently in a Phase 2b clinical trial for squamous cell cancer of the head and neck. Additionally, the company is leveraging gene-editing and cell therapy technology to develop treatments for oncology, blood disorders, and monogenic diseases.
